Semaglutide vs Wegovy: What’s the Difference?
Semaglutide is the active ingredient (the molecule); Wegovy is the brand-name version of semaglutide that the FDA approved specifically for chronic weight management. Every Wegovy is semaglutide, but not every semaglutide is Wegovy. Ozempic and Rybelsus are also semaglutide, sold under different brand names for type 2 diabetes. And “compounded semaglutide” is the same molecule made by pharmacies outside the brand-name approval. This page walks through the differences that actually matter: what each name means, which one you get for what indication, what they cost, and whether switching between them makes sense.
Semaglutide vs Wegovy: What’s the Actual Difference?
One is a drug. The other is a brand of that drug approved for one specific use.
Semaglutide is the generic name of a GLP-1 receptor agonist. It is the medication itself: a peptide that mimics the gut hormone GLP-1, slows gastric emptying, and reduces appetite. Semaglutide is manufactured only by Novo Nordisk under patent, and it is sold under three FDA-approved brand names in the United States.
Wegovy is one of those brand names. It is semaglutide packaged and dosed for chronic weight management, and it is the version the FDA approved for that purpose in 2021. Wegovy goes up to a 2.4 mg weekly subcutaneous injection, plus a newer 7.2 mg high-dose option (Wegovy HD) that the FDA approved in March 2026. There is also a once-daily oral Wegovy tablet, approved in December 2025.
So when someone says “I’m on semaglutide for weight loss,” they are almost always on Wegovy or on a compounded version of the same molecule. When someone says “I’m on Wegovy,” they are on semaglutide, specifically the brand approved for weight management.
For a longer walk-through of how the molecule works and why it produces weight loss, see What is semaglutide and how does it work.
The Three FDA-Approved Semaglutide Brands
Same molecule, three different brand names, three different approved uses.
All three brands below are semaglutide made by Novo Nordisk. What separates them is the FDA-approved use, the dose, and how you take it.
| Brand | Form | FDA-approved for | Top dose |
|---|---|---|---|
| Wegovy (injection) | Weekly subcutaneous injection | Chronic weight management (adults and children 12+ with obesity) | 2.4 mg/week (standard), 7.2 mg/week (Wegovy HD, approved Mar 2026) |
| Wegovy (oral) | Once-daily tablet | Chronic weight management (approved Dec 2025) | 25 mg/day |
| Ozempic | Weekly subcutaneous injection | Type 2 diabetes; cardiovascular risk reduction in adults with T2D and heart disease | 2.0 mg/week |
| Rybelsus | Once-daily tablet | Type 2 diabetes | 14 mg/day |
Two things to notice. First, Ozempic is not FDA-approved for weight loss, even though it contains the same active ingredient as Wegovy. Doctors sometimes prescribe it off-label for weight management, but insurance rarely covers Ozempic when the reason on the prescription is weight loss rather than diabetes. Second, the injectable Wegovy dose (2.4 mg) is higher than the top Ozempic dose (2.0 mg), so pound-for-pound weight loss results on Ozempic tend to be slightly smaller than on full-dose Wegovy.
For the week-by-week dosing schedule on Wegovy, see Semaglutide dosage and titration schedule.
Wegovy vs Compounded Semaglutide: What’s the Difference?
Same molecule, different manufacturing and different legal status.
“Compounded semaglutide” is semaglutide made by a compounding pharmacy rather than by Novo Nordisk. During the FDA shortage of brand-name semaglutide, licensed compounders were legally allowed to prepare it for patients. The FDA declared the semaglutide shortage resolved in February 2025, which narrowed that legal window sharply. Under current rules, most 503A patient-specific compounding of semaglutide is only permitted when a specific patient need cannot be met by the brand-name drug (for example, an allergy to an inactive ingredient, or a required dose that is not commercially available).
Practically, this means:
- Wegovy is FDA-approved. Manufactured in FDA-inspected facilities, tested for purity and potency, sold in preassembled pens with printed dose indicators. Insurance may cover it if your plan includes weight-loss medications.
- Compounded semaglutide is not FDA-approved. Purity, potency, and sterility depend on the specific pharmacy. Some compounders operate under strong quality standards (USP 795/797, LegitScript certification, board-certified pharmacists on staff); others do not. Insurance does not cover it. It is cash-pay.
The dose is typically the same active molecule at the same milligram amount, but the delivery is different: compounded semaglutide is usually sold in multi-dose vials with a separate syringe, not a preassembled pen. That format is cheaper to produce, which is part of why compounded prices land around $150 to $400 per month while brand-name Wegovy without insurance runs closer to $1,300 to $1,400 per month.
For a deeper comparison of the two paths, see Compounded vs branded semaglutide and Is Wegovy the same as semaglutide.
Which Costs Less, Wegovy or Generic Semaglutide?
Compounded semaglutide is cheaper in cash. Wegovy is often cheaper with insurance.
There is no true “generic Wegovy.” Semaglutide is under patent through 2032 in the United States, so no generic manufacturer can legally produce it under the Ozempic, Wegovy, or Rybelsus names. The only lower-cost alternatives right now are compounded semaglutide (see above) or the Wegovy savings card, which reduces the cost for people with commercial (employer or marketplace) insurance.
Typical monthly out-of-pocket in 2026:
| How you buy it | Typical monthly cost | What it depends on |
|---|---|---|
| Wegovy with commercial insurance + savings card | As low as $25/month | Insurance must cover weight-loss medication; plan-specific |
| Wegovy self-pay through NovoCare Pharmacy | $349/month | Novo Nordisk’s direct cash-pay program (adjusts periodically) |
| Wegovy at retail pharmacy without coverage | ~$1,350/month | List price |
| Compounded semaglutide (telehealth) | $150 to $400/month | Provider, dose, program duration; not FDA-approved |
| Ozempic (off-label for weight loss) | $0 to ~$970/month | Insurance covers only for T2D; without T2D, usually full price |
For step-by-step on the savings-card path, see the Wegovy and Zepbound savings card guide. To check whether your specific plan covers weight-loss GLP-1s, see the GLP-1 insurance coverage checker.
Do Wegovy and Generic Semaglutide Work the Same?
The molecule is identical. Real-world results depend on dose, consistency, and quality of the source.
The active ingredient in Wegovy and in properly compounded semaglutide is the same peptide. If a compounder delivers the same milligram dose of the same molecule, the pharmacology is the same. That is why compounded semaglutide, when it is real, produces comparable appetite suppression and comparable weight loss trajectories.
Two caveats:
- The dose has to actually reach the full 2.4 mg-equivalent weekly. Some compounded programs cap the dose lower to save cost, or push slower titration. The 15% average weight loss in the STEP 1 trial was on the full 2.4 mg weekly dose. See Semaglutide before and after: what real results actually look like for the distribution of results at that dose.
- Purity varies. Compounded product from a LegitScript-certified 503A pharmacy following USP 795/797 is a different reality than product from an unregulated overseas source labeled “for research use only.” The molecule is the same on paper; what actually gets injected is not always the same in practice.
Side effects are also broadly similar because the mechanism is the same: nausea, constipation, or diarrhea in the early weeks, easing after the first few dose steps for most people. For the timeline and how the common side effects usually resolve, see Semaglutide side effects timeline. For how long it takes to see weight change on the standard schedule, see How long does semaglutide take to work.
Can You Switch Between Wegovy and Generic Semaglutide?
Yes, and many people do. A prescribing provider should manage the transition.
Because the active ingredient is the same, switching from Wegovy to compounded semaglutide (or vice versa) at the equivalent weekly dose does not typically require re-titration. Most people stay on the dose they were already tolerating.
Common reasons people switch:
- From compounded to Wegovy: insurance approved coverage, or the person wants an FDA-approved product going forward, or a compounding pharmacy closed.
- From Wegovy to compounded: lost commercial insurance, hit a prior-authorization wall, or the out-of-pocket became unaffordable.
- From Ozempic to Wegovy: using Ozempic off-label for weight loss and moving to the FDA-approved product for that use so insurance may cover it and dose can go up to 2.4 mg (or 7.2 mg on Wegovy HD).
A prescriber should manage each of these transitions, both to preserve the dose you were tolerating and to make sure the new source or product is legitimate. This is especially important with compounded product; the pharmacy behind the compound matters more than the price on the invoice.